Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

 Blogroll
Olmetec(R) (olmesartan Medoxomil) Is First Angiotensin Receptor Blocker (ARB) To Suggest Atherosclerosis Regression (in Hyperten

Olmetec(R) (olmesartan Medoxomil) Is First Angiotensin Receptor Blocker (ARB) To Suggest Atherosclerosis Regression (in Hyperten

Dec 10 2007 | comment(s)

GERRARDS CROSS, England, December 10 /PRNewswire/ --

- MORE Study Shows Potential for Vascular Benefits in Addition to BP Lowering with olmesartan

ReQall Helps Britain Remember

ReQall Helps Britain Remember

Dec 10 2007 | comment(s)

LONDON, December 10 /PRNewswire/ --

- Free service works with a phone call

reQall (http://www.reqall.com) today announced the launch of a free trial service which will help people across Britain remember better. In the run-up to Christmas, the pressure to remember all those little things is greater than ever. From trying to be better organized, to getting things done early, to taking memory pills ... there are many 'foolproof' solutions. Finally there is, and it's free, and it's available to anybody who owns even the most basic mobile phone. reQall is a new service which allows people to record voice notes, reminders or even short conversations, and then be automatically reminded of them, search for them and recall them weeks, months or even years later.

EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival For AML Patients Treated With Ceplene(TM) + I

EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival For AML Patients Treated With Ceplene(TM) + I

Dec 10 2007 | comment(s)

TARRYTOWN, New York, December 10 /PRNewswire/ --

- First Drug Regimen Shown to Prevent AML Relapse

EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today released new clinical data that demonstrate a durable improvement in leukemia-free survival (LFS) over five years among Acute Myeloid Leukemia (AML) patients who receive post-consolidation immunotherapy with Ceplene(TM) (histamine dihydrochloride) in conjunction with low dose interleukin-2 (IL-2). These data were presented on December 9th at the 49th Annual Meeting of the American Society of Hematology (ASH) in Atlanta.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

Pharmion Presents Clinical Data Demonstrating Significant Survival Advantage Of Azacitidine (Vidaza(R)) In Patients With Myelody

Pharmion Presents Clinical Data Demonstrating Significant Survival Advantage Of Azacitidine (Vidaza(R)) In Patients With Myelody

Dec 09 2007 | comment(s)

ATLANTA, Georgia, December 9 /PRNewswire/ --

- Data Demonstrate 9.4 Month Median Overall Survival Benefit in Higher-risk MDS for Azacitidine Compared to Conventional Care Regimens (Log Rank p=0.0001)

- Two Year Overall Survival Rate of 50.8% for Azacitidine Compared to 26.2% for Conventional Care Regimens

- Highly Consistent Effect Across Patient Subgroups

- Data Presented at the 49th American Society of Hematology Meeting

Fortent Launches Next Generation Anti-Money Laundering Solution

Fortent Launches Next Generation Anti-Money Laundering Solution

Dec 09 2007 | comment(s)

NEW YORK, and DUBAI, United Arab Emirates, December 9 /PRNewswire/ --

- New Fortent AML 6.0 release enhances investigation and correspondent banking features

Fortent has released a new version of the company's market-leading anti-money laundering technology, the company announced today at the Middle East-North Africa International Money Laundering/Terrorist Financing Conference & Exhibition, hosted in Dubai by the Association of Certified Anti-Money Laundering Specialists (ACAMS) and the Union of Arab Banks.

Investors Discuss Koninklijke Philips Electronics N.V.

Investors Discuss Koninklijke Philips Electronics N.V.

Dec 08 2007 | comment(s)

NEW YORK, December 8 /PRNewswire/ --